AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05002049 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: Teenagers with leadership skills from intervention schools (called ambassadors) and stakeholders will participate in focus groups to gain insights on the barriers and facilitators for healthy lifestyles of teenagers, and how science could help address these. Building on the information of the focus groups, ambassadors, stakeholders and other peers will participate in a collaborative competition event where the SEEDS intervention(s) will be designed. The intervention(s) will be implemented at intervention high-schools during 6 months. Outcomes in health behaviours and science literacy will be assessed by validated questionnaires at the start and end of the project.
Study NCT04958655 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Tetris Task
Description: a visual task where participants are asked to play 'tetris' i.e. attend to and manipulate shapes and positions on screen
Study NCT04958655 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mental Imagery for Craving Reduction
Description: a behavioural mental imagery intervention where participants are asked to generate a specific future mental image to reduce cue-induced craving for alcohol
Study NCT05623501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydromyricetin
Description: Dose-escalation and lysine preparation
Study NCT05973825 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leucapheresis
Description: leucapheresis is a procedure in which a large amount of blood cells are obtained by an apheresis procedure
Study NCT05720923 — intervention group
Intervention type: DEVICE
Intervention: Analysis with Ergometer
Description: The analysis with the ergometer aims at assessing neuromuscular function
Study NCT05020210 — intervention group
Intervention type: DRUG
Intervention: Sivelestat sodium
Description: Patients were treated with Sivelestat Sodium within 72 hours of the diagnosis of ARDS.
Study NCT06527417 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuro Trac Myo Plus Pro
Description: Electrical stimulation parameters; stimuli were monophasic, rectangular, stimulus duration 300 µs, frequency 25 Hertz, amplitude was increased up to a maximum of 100 milliampere until contraction was seen.
Study NCT06527417 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Trunk eccentric exercises
Description: The control group performed back eccentric exercises for 4 weeks, 3 times a week, 3 times in each session
Study NCT06546852 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: education
Description: Patient education will be provide
Study NCT05603416 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Perilla frutescens extract
Description: oral dissolvable powder - dosage 300mg
Study NCT05603416 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral dissolvable powder - dosage 300mg no active ingredient
Study NCT01297868 — intervention group
Intervention type: OTHER
Intervention: exercise
Study NCT05129072 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: kalifilcon A Daily Disposable Toric LD213001 lens in SKUs +6D, +3D, 0D, -3D, -6D, and -9D
Description: kalifilcon A Daily Disposable Toric LD213001 lens
Study NCT06361823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Giving Semaglutide via subcutaneous injections on a weekly basis for a duration of 3 months. The dosage is 0.25 mg for the initial month, then upped to 0.5 mg for patients who could handle it in the second month, and eventually escalated to 1.0 mg for patients who continued to tolerate it in the third month.
Study NCT06361823 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low calorie diet
Description: Low calorie diet (max 1200 kcal/day)
Study NCT06361823 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low calorie diet
Description: Low calorie diet (max 1200 kcal/day)
Study NCT05881473 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: pain assessment after clavicular fracture repair
Description: This group includes (40) patients will have medial and lateral clavipectoral (CPB) block ultrasound guided using 20 ml Bupivacaine 0.5% for medial and lateral block equally after induction of general anesthesia.
Study NCT06520709 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT05640245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonelokimab
Description: randomized treatment; parallel group
Study NCT05640245 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: randomized treatment; parallel-group
Study NCT05640245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: randomized treatment; parallel-group
Study NCT05639556 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: BMI and lean mass index from DXA
Description: Estimate and compare correlation between lean mass index from DXA and BMI
Study NCT05639556 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Anthropometric Measurements
Description: Skinfold will be assessed with calipers. Circumference will be measured with a tape measure.
Study NCT05169424 — intervention group
Intervention type: DEVICE
Intervention: Trelegy Ellipta
Description: Trelegy Ellipta
Study NCT05169424 — intervention group
Intervention type: DEVICE
Intervention: Stiolto Respimat
Description: Stiolto Respimat
Study NCT05169424 — intervention group
Intervention type: DRUG
Intervention: Tiotropium + Olodaterol (5/5 mcg)
Description: Tiotropium + Olodaterol (5/5 mcg)
Study NCT05169424 — intervention group
Intervention type: DRUG
Intervention: Fluticasone Furoate + Umeclidinium + Vilanterol (100/62.5/25 mcg)
Description: Fluticasone Furoate + Umeclidinium + Vilanterol (100/62.5/25 mcg)
Study NCT05854979 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Gastric Ultrasound
Description: A gastric ultrasound will be completed on every patient and administered the same way in each arm. The patient will be placed in supine position. A curvilinear ultrasound probe will be placed on the sagittal plane below the xiphoid process. The probe will then slide along the costal margin to the right until the gastric antrum is identified. At this point, the ultrasound image will be obtained, and appropriate measurements will be taken. The patient will be placed in the right lateral decubitus position and the above procedure will be repeated.
Study NCT05616338 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: A blood sample and a nasal brush for each participant. The nasal brushing will allow the isolation of epithelial cells that will serve as a comparison for the bronchial tissue produced from blood-derived iPS.~A blood sample of approximately 14 ml will be taken for isolation and freezing of the blood mononuclear cells allowing the generation of iPS.
Study NCT05639556 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hand-grip strength
Description: A small, handheld dynamometer will be used to measure grip strength, a measure of function, on each hand.
Study NCT05639556 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Six-minute walk Test
Description: This will be another functional assessment of fitness. Participants will be asked to walk at their normal pace for 6 minutes.The total distance walked in that time will be measured.
Study NCT05751707 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Frequency Chest Wall Oscillations via The Vest® Airway Clearance System
Description: High Frequency Chest Wall Oscillations via The Vest® Airway Clearance System is a clinical device which consists in a pump which generates high frequency oscillations and connected to a jacket worn by the patient, intended to facilitate airway secretions clearance by detaching them from the bronchial wall and moving them upwards in the bronchial system.
Study NCT05639556 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Sit-to-Stand Test
Description: This will be used as a functional assessment of fitness and lower extremity strength. Participants will start seated on a chair and be asked to complete as many sit-to-stand repetitions without using their arms for one minute.
Study NCT05639556 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Short physical performance battery (SPPB)
Description: This is an assessment of frailty. The test is completed in approximately 8 minutes. The test consists of 3 assessments: 1) Balance tests where the participant stands and tries to balance with their feet in various positions for 10 seconds each without assistance (side-by-side, heel-to-side, and heel-to-toe); 2) Two 4-meter gait speed tests; and 3) Chair-stand tests (single chair stand, 5 chair stands).
Study NCT05639556 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: BIA Sub-study
Description: A minimum of 50 individuals will be enrolled. Body composition will be assessed at each study visit using study bioelectrical impendence analysis (BIA).
Study NCT05639556 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Accelerometry to assess physical activity
Description: Participants will be provided with a wrist-worn accelerometer/heart rate monitor at the baseline study visit and asked to wear it continuously for at least 3-10 days (two weekdays, one weekend day). Approximately every 3 months, the participant will be asked to again wear the accelerometer. Participants will be able to keep their accelerometers.
Study NCT05977023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMDAE
Description: Use of an NMDA enhancer for the treatment of bipolar depression
Study NCT05977023 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cap
Description: Use of placebo as a comparator.
Study NCT05806996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium
Description: Intravenous infusion, load 50 mg/Kg with infusion of 15 mg/Kg/hour
Study NCT05806996 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Equivalent volume of normal saline
Study NCT06252883 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Serial bedside video call communication
Description: Bedside video call with audio features, given to NICU parent/guardian 2-3 days a week for an 8-week period or till infant is discharged, whichever comes first.
Study NCT04722497 — intervention group
Intervention type: OTHER
Intervention: Sound Education
Description: All physicians and nurses involved in cesarean births will be given an education intervention explaining the impact of noise levels on stress and focus. The SoundEar device will be used as an intervention tool to inform operating room physicians and nurses when the noise level is above the desired level.
Study NCT05148091 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTV01C
Description: A Recombinant Trimeric S Protein Vaccine against SARS-CoV-2 Alpha and Beta Variants
Study NCT05148091 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Adjuvant
Description: SCT-VA02B is the adjuvant of SCTV01C VACCINE applied as one of the control in the trial
Study NCT05148091 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline is used as the other control in the trial
Study NCT06351059 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: InModi acoustic emission analysis
Description: All diagnosis tests
Study NCT05344898 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subscap Tenotomy
Description: Group will not have their subscapularis tendon repaired following a reverse shoulder replacement.
Study NCT05344898 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subscap Repair
Description: Group will have their subscapularis tendon repaired following a reverse shoulder replacement.
Study NCT05812014 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Bivalent mRNA vaccine (LVRNA021)
Description: One dose was administered by intramuscular injection, 100μg，1.0ml/dose
Study NCT05812014 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride solution
Description: One dose was administered by intramuscular injection, 1.0ml/dose
Study NCT05639556 — intervention group
Intervention type: OTHER
Intervention: Gastrointestinal (GI) and nutrition questionnaires:
Description: Subjects will complete surveys regarding gastrointestinal (GI) symptoms, including the Patient Assessment of Constipation (PAC-SYM) Score, Patient Assessment of Gastrointestinal Symptoms (PACGI-SYM) Score, the Bristol Stool Chart, and the scored Patient-Generated Subjective Global Assessment (PG-SGA).
Study NCT04817228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EscharEx (EX-02 formulation)
Description: EscharEx (EX-02 formulation) gel is topically applied on a wound surface of up to 80 cm2 , up to 8 consecutive applications or until a complete debridement is achieved, whichever occurs first.
Study NCT05271656 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-Scan System
Description: Subjects will be provided with contrast agent and dietary fiber pills, and instructed to start intake of fiber pills 5 days, and contrast agent 48 hours prior to scheduled C-Scan capsule ingestion. C-Scan system intervention includes ingestion of the C-Scan Cap and attachment of the C-Scan Track to the subject's lower back. The subject is required to keep the C-Scan Track attached to the lower back and to continue intake of contrast agent and dietary fiber pills until the C-Scan Cap's natural excretion. Standard of care optical colonoscopy will be performed within 60 days from the C-Scan Cap ingestion.
Study NCT03999840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemdisiran
Description: Cemdisiran has been designed to reduce the level of C5 mRNA in the liver, thereby reducing levels of circulating C5 protein, inhibiting terminal complement pathway activity, and preventing formation and deposition of the MAC (C5-b9) on endothelial cells in the kidney.
Study NCT05639556 — intervention group
Intervention type: OTHER
Intervention: Psychosocial questionnaire: PHQ-8
Description: This is an 8-item scale that measures depressive symptoms over the past two weeks.
Study NCT03999840 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: The control drug for this study will be a placebo (sodium chloride 0.9% w/v for SC administration). Placebo will be prepared and labelled identically to cemdisiran.
Study NCT05639556 — intervention group
Intervention type: OTHER
Intervention: Psychosocial questionnaire: GAD-7
Description: This is a 7-items scale that measures anxiety symptoms over the past two weeks, from not at all to nearly every day.
Study NCT04698993 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Dräger Antigen Test SARS-CoV-2
Description: Collection of patient samples using the Dräger sample collector with subsequent test reading via the Dräger Antigen SARS-CoV-2 Test
Study NCT06388798 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Psychoeducational training
Study NCT04860141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin 600mg
Description: The patient will take gabapentin 600mg 2 hours prior to the procedure
Study NCT04860141 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: the patient will take a pill that looks like gabapentin 2 hours prior to the procedure
Study NCT06272123 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT06507826 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Compassionate Writing for Caregivers of Older Adults
Description: Self-compassionate writing focusing on one or more self-compassion components (mindfulness, self-kindness, common humanity).
Study NCT06507826 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Self-Compassionate Writing for Caregivers of Older Adults
Description: Self-compassionate writing focusing on one or more self-compassion components (mindfulness, self-kindness, common humanity).
Study NCT06393647 — intervention group
Intervention type: OTHER
Intervention: Frailty scale forms (Frailty Scale Version 9, Quality of Life Scale Short Form-36)
Description: In our study, we aim to investigate the relationship between frailty status assessed using frailty scale forms (Frailty Scale Version 9, Quality of Life Scale Short Form-36) and preoperative levels of Albumin/Creatinine, B12, Folate, Ferritin, Sedimentation Rate, and CRP in patients undergoing gastrointestinal malignancy surgery.
Study NCT05386693 — intervention group
Intervention type: PROCEDURE
Intervention: Ilioinguinal nerve block
Description: Local anesthetic injection of the ilioinguinal nerve. This is performed in the outpatient clinic.
Study NCT04745897 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eTB Catalogue of Recommendations (eTB)
Description: eTB Catalogue of Recommendations (eTB)
Study NCT04745897 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: World Health Organization Tuberculosis Website (WHO TB)
Description: World Health Organization Tuberculosis Website (WHO TB)
Study NCT05769959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7515629
Description: RO7515629 will be administered intravenously at a dose and schedule as specified for the respective study part and cohort.
Study NCT05769959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab
Description: Tocilizumab will be used as rescue medication only. Tocilizumab will be administered as required for the management of cytokine release syndrome (CRS).
Study NCT04809142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450 Injection
Description: TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle.
Study NCT04809142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib hydrochloride
Description: Anlotinib capsules 12 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
Study NCT04809142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin injection
Description: Oxaliplatin injection 130 mg/m2 administered IV on Day 1 of each week in 3-week cycles;
Study NCT04809142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine tablets
Description: Capecitabine tablets total dose 2000 mg/m2, oral twice a day from Day 1-14 of each 3- week cycles;
Study NCT04809142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine hydrochloride injection
Description: Gemcitabine hydrochloride injection administered 1000 mg/m2 IV on Day 1 and Day 8 of each week in 3-week cycles.
Study NCT05639556 — intervention group
Intervention type: OTHER
Intervention: Psychosocial questionnaire: The Treatment Self-Regulation Questionnaire (TSRQ)
Description: This is a 15-item scale that assesses the degree to which participants' motivation is autonomous or self-regulated.
Study NCT05639556 — intervention group
Intervention type: OTHER
Intervention: Psychosocial questionnaire: CF Fatalism Scale
Description: The CF Fatalism Scale measures the belief in a lack of personal power or control over one's future and has 13 items.
Study NCT05118399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Injection [Marcaine]
Description: Bupivacaine injection \[Marcaine\] is the standard treatment used in our hospital.
Study NCT05118399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Liposome 13.3 MG/ML [Exparel]
Description: Bupivacaine liposome is a multivesicular formulation of bupivacaine that allows rapid absorption and prolonged release of bupivacaine.
Study NCT04924998 — intervention group
Intervention type: DRUG
Intervention: current treatment of AL-CM
Description: current treatment of AL-CM
Study NCT04686955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiao-Xian-Gui-Fu-Tang
Description: The Xiao-Xian-Gui-Fu-Tang includes Xiao-Feng-San 2.0g, Dang-Gui-Yin-Zi 1.2g, Bai-Xian-Pi(Cortex Dictamni Radicis) 0.4g, and Di-Fu-Zi(Fructus Kochiae) 0.5g. The Xiao-Xian-Gui-Fu-Tang will be manufactured, packaged, and labeled by the KO DA Pharmaceutical Company (Taiwan), using good manufacturing practice standards.
Study NCT04686955 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Xiao-Xian-Gui-Fu-Tang
Description: The Xiao-Xian-Gui-Fu-Tang includes Xiao-Feng-San 2.0g, Dang-Gui-Yin-Zi 1.2g, Bai-Xian-Pi(Cortex Dictamni Radicis) 0.4g, and Di-Fu-Zi(Fructus Kochiae) 0.5g. The Xiao-Xian-Gui-Fu-Tang will be manufactured, packaged, and labeled by the KO DA Pharmaceutical Company (Taiwan), using good manufacturing practice standards.
Study NCT05466357 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Excision of pituitary tumor outside pseudocapsule
Description: Dedicated high-resolution magnetic resonance imaging (MRI) protocols have been proposed to detect pituitary adenoma and accurately guide surgical removal. To accomplish complete PA removal and minimize the impact on pituitary functions, intraoperative navigation was used to identify the tumor pseudocapsule. Depending on different tumor sizes and pseudocapsule development, investigators adopted different resection strategies. The suspicious tissue was sent to the pathology department for histopathology intraoperatively. Long-term postoperative follow-up imaging and endocrine data were used to evaluate tumor prognosis before and after operation. Standardized management and established biobank is critical for pituitary adenomas.
Study NCT05639556 — intervention group
Intervention type: OTHER
Intervention: Psychosocial questionnaire: Body Esteem Scale for Adolescents and Adults (BESAA)
Description: The Body Esteem Scale for Adolescents and Adults (BESAA) is 23-item measurement of self-evaluations of one's body or appearance.
Study NCT06256393 — intervention group
Intervention type: OTHER
Intervention: Collection of biological samples
Description: Collection of blood samples and intestinal biopsies during a surgery or colonoscopy for disease relapse